REMS Regulatory Developments
and Best Practices

Friday, March 22, 2019 · 1:30 p.m. - 3:00 p.m. EDT

Is your REMS program compliant with new FDA expectations?

Lynn Mehler — partner in the Hogan Lovells pharmaceutical and biotechnology practice will address the FDA’s current expectations in designing a program to assess REMS, and how to make your program compliant with those expectations. You’ll learn about:

  • How REMS assessments have changed over the more than 10 years since REMS was enacted
  • The FDA’s current expectations in designing a program to assess REMS and how to make your program compliant
  • The REMS assessment process, including what goes on behind the scenes
  • How REMS assessments can lead to additional requirements, separate and apart from modifications to a REMS
  • How to use REMS assessments to build a case for REMS modification including elimination of requirements
  • How to comply with two significant recent guidances, Development of a Shared System REMS and Waivers of the Single, Shared System REMS Requirement

You’ll come away with a deeper understanding of the FDA’s current approach to REMS, including the increased focus on and complexity of the REMS assessment process. Register today.

Who Will Benefit

  • Regulatory and quality professionals
  • Executive suite
  • Regulatory affairs/compliance
  • Medical affairs/pharmacovigilance
  • Product lifecycle managers
  • Labeling specialists
  • Risk managers
  • General/corporate counsel
  • Outside attorneys

Webinar plus USB Audio Recording/Transcript
Learn more

$487

add to cart

Webinar only
Learn more

$287

add to cart

24/7 Encore plus USB Audio Recording/Transcript
Learn more

$487

add to cart

24/7 Encore Presentation
Learn more

$287

add to cart

USB Audio Recording/Transcript
Learn more

$287

add to cart

 

 

 

Meet Your Presenter

Lynn Mehler

Partner
Hogan Lovells

Lynn Mehler, partner in the Hogan Lovells Pharmaceutical and Biotechnology practice, advises clients on a range of FDA and DEA regulatory matters. Drawing on her 12 years with the FDA's Office of the Chief Counsel, Lynn has a deep understanding of the FDA. She advised the agency on drug safety matters, including at approval and those leading to labeling changes, REMS, and product withdrawal.  Lynn works with a range of clients on REMS matters, from developing, assessing and modifying REMS, to negotiating shared REMS with generic applicants.

MII logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.

Phone (703) 538-7600 | Fax (703) 538-7676 | Toll free (888) 838-5578 | Email customerservice@fdanews.com

© 2019 FDAnews